Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Type C Meeting Timings

<< Previous

Bullboard Posts

Next >>

Comment by Quentin30on Apr 11, 2024 7:20pm

86 Views

Post# 35984518

RE:RE:RE:RE:RE:RE:RE:RE:RE:Type C Meeting Timings

jumping the gun again Canaduh...

1) NO FDA meetings have been announced... ONCY has petitioned a meeting. The FDA may reject the request.. we don't know... and neither do you.

2) If you have seen the Type C Meeting Package then you know what is in it... this MAY be about the trial design, but won't be for the trial design... that will be submitted in the phase III protocol...

It's more likely that ONCY will be seeking agreement on the use of a biomarker in the Phase III, which will inform the trial size.

I know you try to be helpful in explaining things, but explaining them incorrectly doesn't help anyone... do you agree.?

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024